USA Conjugate Vaccine Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Conjugate Vaccine Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Haemophilus B Market Performance (Volume)
  • 2.1.2 Monovalent Market Performance (Volume)
  • 2.1.3 Multivalent Market Performance (Volume)
  • 2.1.4 Others Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Haemophilus B Market Performance (Value)
  • 2.1.2 Monovalent Market Performance (Value)
  • 2.1.3 Multivalent Market Performance (Value)
  • 2.1.4 Others Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Influenza Market Performance (Volume)
  • 3.1.2 Pneumococcal Market Performance (Volume)
  • 3.1.3 Meningococcal Market Performance (Volume)
  • 3.1.4 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Astellas Pharma Inc
  • 4.1.1 Astellas Pharma Inc Profiles
  • 4.1.2 Astellas Pharma Inc Product Information
  • 4.1.3 Astellas Pharma Inc Conjugate Vaccine Business Performance
  • 4.1.4 Astellas Pharma Inc Conjugate Vaccine Business Development and Market Status
• 4.2 CSL Limited
  • 4.2.1 CSL Limited Profiles
  • 4.2.2 CSL Limited Product Information
  • 4.2.3 CSL Limited Conjugate Vaccine Business Performance
  • 4.2.4 CSL Limited Conjugate Vaccine Business Development and Market Status
• 4.3 Emergent BioSolutions
  • 4.3.1 Emergent BioSolutions Profiles
  • 4.3.2 Emergent BioSolutions Product Information
  • 4.3.3 Emergent BioSolutions Conjugate Vaccine Business Performance
  • 4.3.4 Emergent BioSolutions Conjugate Vaccine Business Development and Market Status
• 4.4 GlaxoSmithKline
  • 4.4.1 GlaxoSmithKline Profiles
  • 4.4.2 GlaxoSmithKline Product Information
  • 4.4.3 GlaxoSmithKline Conjugate Vaccine Business Performance
  • 4.4.4 GlaxoSmithKline Conjugate Vaccine Business Development and Market Status
• 4.5 Johnson&Johnson
  • 4.5.1 Johnson&Johnson Profiles
  • 4.5.2 Johnson&Johnson Product Information
  • 4.5.3 Johnson&Johnson Conjugate Vaccine Business Performance
  • 4.5.4 Johnson&Johnson Conjugate Vaccine Business Development and Market Status
• 4.6 MedImmune
  • 4.6.1 MedImmune Profiles
  • 4.6.2 MedImmune Product Information
  • 4.6.3 MedImmune Conjugate Vaccine Business Performance
  • 4.6.4 MedImmune Conjugate Vaccine Business Development and Market Status
• 4.7 Merck
  • 4.7.1 Merck Profiles
  • 4.7.2 Merck Product Information
  • 4.7.3 Merck Conjugate Vaccine Business Performance
  • 4.7.4 Merck Conjugate Vaccine Business Development and Market Status
• 4.8 Pfizer
  • 4.8.1 Pfizer Profiles
  • 4.8.2 Pfizer Product Information
  • 4.8.3 Pfizer Conjugate Vaccine Business Performance
  • 4.8.4 Pfizer Conjugate Vaccine Business Development and Market Status
• 4.9 Sanofi Pasteur
  • 4.9.1 Sanofi Pasteur Profiles
  • 4.9.2 Sanofi Pasteur Product Information
  • 4.9.3 Sanofi Pasteur Conjugate Vaccine Business Performance
  • 4.9.4 Sanofi Pasteur Conjugate Vaccine Business Development and Market Status
• 4.10 Serum Institute
  • 4.10.1 Serum Institute Profiles
  • 4.10.2 Serum Institute Product Information
  • 4.10.3 Serum Institute Conjugate Vaccine Business Performance
  • 4.10.4 Serum Institute Conjugate Vaccine Business Development and Market Status
• 4.11 India Pvt

5 Market Performance for Manufacturers

• 5.1 USA Conjugate Vaccine Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 USA Conjugate Vaccine Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 USA Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 USA Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Northeast Market Performance for Manufacturers
  • 6.1.1 Northeast Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Northeast Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Northeast Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Northeast Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Midwest Market Performance for Manufacturers
  • 6.2.1 Midwest Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Midwest Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Midwest Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Midwest Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Market Performance for Manufacturers
  • 6.3.1 South Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 West Market Performance for Manufacturers
  • 6.4.1 West Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 West Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 West Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 West Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration

7 USA Conjugate Vaccine Market Performance (Sales Point)

• 7.1 USA Conjugate Vaccine Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 USA Conjugate Vaccine Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 USA Conjugate Vaccine Price (USD/Unit) by Regions 2013-2018
• 7.4 USA Conjugate Vaccine Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 USA Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Northeast Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Midwest Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 West Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Influenza Industry
• 11.2 Pneumococcal Industry
• 11.3 Meningococcal Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 USA Conjugate Vaccine Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 USA Conjugate Vaccine Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Northeast Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Midwest Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 West Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Conjugate Vaccine Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Haemophilus B Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Monovalent Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Multivalent Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Influenza Sales and and Growth Rate 2019-2024
  • 12.4.3 Pneumococcal Sales and and Growth Rate 2019-2024
  • 12.4.4 Meningococcal Sales and and Growth Rate 2019-2024
  • 12.4.5 Others Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 USA Conjugate Vaccine Price (USD/Unit) Trend 2019-2024
  • 12.5.2 USA Conjugate Vaccine Gross Profit Trend 2019-2024

13 Conclusion